Aegerion Pharmaceuticals Inc. (AEGR) provided a clinical update on its lead investigational therapeutic, lomitapide.
Aegerion reported that the 78-week data from its pivotal Phase III clinical trial are consistent with data previously reported at the 26- and 56-week time points. The Phase III study was a single-arm, open label trial, designed to evaluate the efficacy and long-term safety of lomitapide for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). The data demonstrate that the reduction in LDL-C cholesterol from baseline was maintained at 78-weeks.
Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, in clinical development as an oral, once-a-day therapeutic for HoFH.
For comments and feedback: editorial@rttnews.com